You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Cautious excitement, relief after Pfizer vaccine result: What happens next?

The vaccine is the first to be tested in the United States to generate late-stage data

Pfizer | Coronavirus Vaccine

IANS  |  New York 

The results have not been peer-reviewed by outside scientists or published in a medical journal.

Stock markets are booming, scientists are hailing Pfizer's vaccine which has shown 90 percent effectiveness and corporates are already imagining the sunny prospect of a return to on-campus work but is reminding everyone that it still needs to check off three boxes before its silver bullet progresses toward emergency use authorisation.

explains that there needs to be "success" in the following three areas: Evidence of efficacy in most vaccinated patients, evidence of safety with data from thousands of patients and manufacturing which is consistently at the highest quality standards.

Early Monday, and German partner BioNTech released efficacy results from a late stage study of its Covid-19 vaccine candidate 'BNT162b2'. The company reported it was 90 per cent effective after looking at 94 infections in a study that has enrolled more than 43,000 people in the US and five other countries. Some got the vaccine, others got dummy shots.

The Phase 3 clinical trial began on July 27. Nearly 39,000 people have received a second dose of the vaccine candidate by November 8, 2020.

The next milestone for Pfizer and BioNTech is the third week of November. By then a median of 60 days of safety data will be available, as required by the FDA in its guidance for potential Emergency Use Authorization.

The Pfizer - BioNTech shot is one among 10 vaccine candidates in late-stage testing globally. Moderna, another US pharma giant, is also optimistic. Dr. Anthony Fauci, the US government's top-infectious disease expert, said today that Moderna's vaccine is also likely to work out.

In an interview with Bloomberg, William Moss of Johns Hopkins' International Vaccine Access Center laid out three questions that still need answers, despite the hugely encouraging despatch from Pfizer today: "How long does this protection last? What kind of disease did this prevent? Was it mild or severe?"

"They are telling us whether the vaccine protects against the disease, they are not telling us whether it prevents transmission."

Moss said that if people let up on masking up and social distancing thinking that the vaccine has arrived and not knowing if it stops transmission (too), the effects may be seen in rising cases as a result of letting up on proven safety behaviours.

Based on current projections, Pfizer and BioNTech expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.

Dr Fauci said the results of the Pfizer vaccine's 90 per cent effectiveness are "just extraordinary".

"Not very many people expected it would be as high as that. It's going to have a major impact on everything we do with respect to COVID," Fauci said in a call with reporters.

Stocks are surging and Wall Street is climbing merrily back to record heights. Although the vaccine news is not a quick fix, the reaction is one of sheer relief.

"Good for earnings, good for consumer behaviour, good all around" is the word on the street, according to Bloomberg Intelligence, during post-lunch trading in New York.

Confirmed infections in the United States shot past the 10 million mark and more than a quarter million Americans (237,000) are dead from the virus.



(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, November 10 2020. 07:15 IST